Omeros Corporation to Present at the Wedbush 2013 Life Sciences Management Access Conference

SEATTLE, Aug. 8, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that it will present at the Wedbush 2013 Life Sciences Management Access Conference next week. Gregory A. Demopulos, M.D., chairman and chief executive officer, is scheduled to present at 9:45 a.m. Eastern Time on Wednesday, August 14, 2013.

The presentation will be webcast. The live and archived webcasts can be accessed on the “Events” page of the Company’s website at www.omeros.com.

About Omeros Corporation
Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system. The Company’s most clinically advanced product candidates, OMS302 for lens replacement surgery and OMS103HP for arthroscopy, are derived from its proprietary PharmacoSurgery platform designed to improve clinical outcomes of patients undergoing a wide range of surgical and medical procedures. Omeros has six clinical development programs. Omeros may also have the near-term capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the market. Behind its clinical candidates and GPCR platform, Omeros is building a diverse pipeline of protein and small-molecule preclinical programs targeting inflammation, coagulopathies and central nervous system disorders.

SOURCE Omeros Corporation